Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00289-w
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00305-z
ICD-11: Impact on Traditional Chinese Medicine and World Healthcare Systems
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00295-y
Lay Summaries of Clinical Study Results: An Overview
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00285-0
Combined Liquid Chromatography-mass Spectrometry and Next-generation DNA Sequencing Detection of Adulterants and Contaminants in Analgesic and Anti-inflammatory Herbal Medicines
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00314-y
Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00269-0
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00288-x
Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00307-x
The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00309-9
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00267-2
Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00279-y
Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00274-3
Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, Observational Study to Assess Effectiveness of Risk-Minimisation Measures
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00291-2
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00280-5
Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00278-z
Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00304-0
Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00287-y
Association of Adverse Drug Events with Hospitalization Outcomes and Costs in Older Adults in the USA using the Nationwide Readmissions Database
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00286-z
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00270-7
Including Traditional Chinese Medicine Diagnoses in ICD-11 May Not Advance the Evaluation of Traditional Chinese Medicine Therapies
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00297-w
ITS2: An Ideal DNA Barcode for the Arid Medicinal Plant Rhazya Stricta
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00266-3
Current Landscape of Late-Phase Clinical Trials for Alzheimer’s Disease: Comparing Regional Variation Between Subjects in Japan and North America
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00306-y
Genome Editing: Promoting Responsible Research
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00276-1
Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00317-9
Evaluation of the Implementation of Additional Risk Minimization Activities in Europe, the USA, and Japan
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00303-1
Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00302-2
Major Pharmaceutical Conferences and Courses
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00312-0
Danish Physicians’ Views on the Appropriateness of the Involvement of Patients with Type 2 Diabetes in Regulatory Decision Making: A Qualitative Study
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00275-2
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00301-3
Design and Analysis of Biosimilar Switching Studies
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00296-x
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00321-z
Correction to: Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00319-7
Liver Test Monitoring: Real-World Compliance for Drugs with Monitoring Requirements at 2-Week Intervals or More Frequently
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00294-z
The Pharmaceutical Year That Was, 2019
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00313-z
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00311-1
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00283-2
Major Pharmaceutical Conferences and Courses
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00290-3
Major Pharmaceutical Conferences and Courses
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00300-4
Forum
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00271-6
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00281-4
Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient Registries
来源期刊:Pharmaceutical MedicineDOI:10.1007/s40290-019-00316-w